ALKS

Alkermes (ALKS) has kicked off a phase 2 trial for ALKS 7290 in adults with major depressive disorder, a development that refocuses attention on the stock’s central nervous system pipeline.

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) has drawn investor attention after recent trading left the shares about 12% lower over the past month and roughly 23% lower over the past 3 months, despite a solid year-to-date gain.

Baird Equity Asset Management recently released its “Small/Mid Cap Growth Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here.

LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.

Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD).

In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult ADHD symptoms over 14 days with a generally well-tolerated safety profile.

Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's conf